Kornimate/medical-research-clean huggingface dataset:
parenting skills for mothers with borderline personality disorder (bpd)

Conditions: Borderline Personality Disorder; Mothers

Summary: the first disorder-specific parenting training program for mothers with borderline personality disorder (m-bpd) is evaluated in a randomized controlled trial. the training program is expected to have positive effects on parenting behavior, decrease the risk of maltreatment of the child, and improve emotion regulation in mothers at post treatment and at 6-month follow-up compared to a control group (treatment as usual; tau). additionally, disorder-specific aspects of dysfunctional parenting behavior as well as bpd-specific aspects of child maltreatment are compared to a clinical control group (mothers with anxiety and/or depression, m-ad/d) and a healthy control group (m-con). to assess the differential development of parenting, the risk of maltreatment and emotion dysregulation in untreated m-bpd are compared to m-con. the investigators expect the difference to increase over time, indicating a worsening in bpd parenting.


Eligibility criteria:
inclusion criteria for mothers with bpd: 1. diagnosed with bpd (assessed via scid-pd) 2. running or completed therapy for bpd symptoms 3. child between 6 months and 6 years 4. living with child or regular (weekly) contact exclusion criteria for the mothers with bpd 1. acute child endangerment 2. maternal acute suicidality 3. maternal psychotic symptoms (assessed via scid-cv) 4. maternal acute alcohol or drug dependency (assessed via scid-cv) 5. maternal diagnosed intellectual disability. inclusion criteria for mothers with depression and/or anxiety disorders: 1. diagnosed with acute affective or anxiety disorder (assessed via scid-cv) 2. child between 6 months and 6 years 3. living with child or regular (weekly) contact exclusion criteria for mothers with depression and/or anxiety disorders: 1. acute child endangerment 2. maternal acute suicidality 3. maternal psychotic symptoms (assessed via scid-cv) 4. maternal acute alcohol or drug dependency (assessed via scid-cv) 5. maternal diagnosed intellectual disability 6. lifetime diagnosis of bpd (assessed via scid-pd) inclusion criteria for healthy control group: 1. child between 6 months and 6 years 2. living with child or regular (weekly) contact exclusion criteria for the healthy control group: 1. acute child endangerment 2. maternal acute suicidality 3. maternal psychotic symptoms (assessed via scid-cv) 4. maternal acute alcohol or drug dependency (assessed via scid-cv) 5. maternal diagnosed intellectual disability. 6. lifetime diagnosis of bpd (assessed via scid-pd) 7. any acute mental disorder (assessed via scid-cv) 8. current psychotherapy
long-term impact of human papillomavirus (hpv) on quality of life

Conditions: Squamous Cell Carcinoma of the Oropharynx

Summary: the investigators are doing this study to learn about the quality of life patients have at the end of treatment. some patients' cancers are related to human papilloma virus or hpv; others are not. hpv is a virus that can be sexually transmitted and is known to cause some types of cancers. if your throat cancer was related to hpv, your doctor can discuss this with you in detail. the investigators want to see if there are differences in quality of life between patients whose cancers are caused by hpv and those who cancers are not caused by hpv. throat cancers caused by hpv behave differently than throat cancers not caused by hpv. the investigators believe that patients with these two different types of throat cancer will also have different experiences after completing therapy. the investigators would like to understand what those differences are. the long-term goal of this study is to see what symptoms most patients have. the investigators can then try to treat them earlier, and hopefully, improve the symptoms. the investigators will also be able to plan more research to improve treatment for symptoms following treatment for cancer of the mouth and throat.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * diagnosis of squamous cell carcinoma of the oropharynx confirmed by the pathology department at mskcc * completed last treatment for oropharynx cancer (surgery, chemotherapy, or radiation) at least 12 months and no more than 5 years before the date of study enrollment * known tumor status or tumor available for hpv testing \[based on chromogenic in situ hybridization with wide spectrum hpv probe (hpv iii family 16 probe (ventana) with affinity to hpv genotypes 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, and 66) or p16 immunohistochemistry done in a clinical laboratory improvement amendment (clia)-approved laboratory; if either of these 2 tests are positive, the patient is classified as positive\]. * able to speak and read english (study questionnaire-aim 1 and interview guide-aim 2 are currently only available in english). * received at least one component of treatment for oropharynx cancer at mskcc or the regional network sites * if radiation therapy was part of treatment, it must have been delivered at mskcc or the regional network sites * for aim 2 only, diagnosed with an hpv+ oropharynx cancer and have knowledge of this diagnosis prior to study enrollment exclusion criteria: * diagnosed with recurrent disease following completion of primary curative treatment

Keywords: survivor human papillomavirus (hpv) quality of life surviving oropharynx cancer 10-111
active surveillance snep assay registry trial for prostate cancer

Conditions: Prostate Cancer Aggressiveness

Summary: a multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.

the analysis population is defined as all the set of de-identified patient results received from the practices who met the inclusion / exclusion criteria. a target recruitment of 2000 subjects with an expected loss of 20% (400 subjects) and an overall event rate of 30% (480 subjects of 1600) will result in 480 cases and 1120 controls, where cases are defined as those patients with nccn unfavorable intermediate risk or worse disease. with a significance level alpha of 0.05, the number of cases above will result in a statistical power (1-ß=0.2) of at least 80% to show a significant increase in performance of the full assay over clinical variables alone, assuming that performance characteristics are similar to those observed in a retrospective, independent training cohort and that the patients in the safely cohort resemble this same training population.

Eligibility criteria:
inclusion criteria * men between 40-80 of age with at least a 10-year life expectancy * all active surveillance protocols are accepted * no psa limits category 1: * patient is currently on active surveillance with only one previous low grade prostate biopsy. * patient must already be scheduled for their 1st annual biopsy under their active surveillance protocol within 90 days of enrollment date. category 2: • patient is recently diagnosed with low grade prostate cancer but has decided against active surveillance and is scheduled for radical prostatectomy within 90 days of enrollment date. exclusion criteria: men on watchful waiting i.e. those with less than 10-year life expectancy with no intent for curative therapy * men with symptoms or rising psa who have not been proven to have cancer by tissue biopsy i.e. men with only negative prostate biopsies. * patients with a history of a different cancer (except basal cell carcinoma)
brilinta taiwan post approval safety study

Conditions: Non ST-elevation Myocardial Infarction

Summary: a multicenter, single arm, open label, phase iv study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of ticagrelor in taiwanese patients with non st-segment (a segment in the eletrocardiogram which presents the period when ventricles are depolarized) elevation myocardial infarction

this study will be conducted in approximately 8 investigational centres in taiwan. it is expected that approximately 100 patients will be enrolled into study treatment. this study is to describe the safety and tolerability of ticagrelor, by assessment of the bleeding events and other serious adverse events (saes) during 1year follow up in taiwanese non st-elevation myocardial infarction (nstemi) patients.

Eligibility criteria:
inclusion criteria: 1. provision of informed consent prior to any study specific procedures 2. female or male aged at least 20 years 3. patient who is considered as ethnic taiwanese 4. index event of non-st elevation myocardial infarction exclusion criteria: 1. contraindication or other reason that ticagrelor should not be administered 2. index event is an acute complication of percutaneous coronary intervention (pci) 3. patient has planned for an urgent coronary artery bypass graft (cabg) within 7 days from the enrolment 4. oral anticoagulation therapy within 30 days prior to enrolment or cannot be stopped 5. fibrinolytic therapy in the 24 hours prior to enrolment, or planned fibrinolytic treatment following enrolment

Keywords: nstemi
endomyocardial botulinum toxin injection in patients with persistent atrial fibrillation

Conditions: Persistent Atrial Fibrillation

Summary: the investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different ablation strategies, pvi plus linear lesions (ll) plus botulinum toxin injection versus pvi plus linear lesions (ll), in patients with persistent or longstanding persistent af. results were assessed with the use of an implanted monitoring device (imd).


Eligibility criteria:
inclusion criteria: * persistent and longstanding persistent af exclusion criteria: * congestive heart failure * lv ejection fraction \< 35% * left atrial diameter \> 60 mm
plac1 in reproduction

Conditions: Pregnancy

Summary: the plac1 gene is a recently described x-linked gene that maps to a region of the x chromosome thought to be important for normal fetal and placental development. elevated levels of plac1 mrna were detected in preeclampsia and appeared to be directly related to disease severity. plac1 may serve as a useful marker of placental dysfunction or threatened pregnancy. the objective of this study is to measure the prevalence of circulating anti-plac1 antibodies in pregnant maternal serum and correlate it with pregnancy outcome. it is likely that women with these antibodies are at higher risk for adverse pregnancy outcomes. approximately 5% (50 of 1000) will be expected to have anti-plac1 antibodies based on previously reported data. the prevalence of these antibodies and their clinical impact on pregnancy outcomes will be determined. 1000 healthy, multiparous and primigravid women will be screened for anti-plac1 antibodies at their routine prenatal clinic visits. subjects will be enrolled at their first clinic visit at usf health, south tampa center, department of obstetrics. blood (1.0 ml) will be obtained as part of the routine blood draw at the time of enrollment. blood will only be collected when drawn as part of routine laboratory testing as determined by the primary care provider. additional blood samples (1.0 ml) will be collected throughout pregnancy at the same time blood is obtained for routine or otherwise clinically indicated laboratory testing. a maximum of 5 samples will be collected through the pregnancy. maternal demographic data will be collected and patients will be followed longitudinally to the completion of pregnancy to ascertain their clinical status during pregnancy, onset of premature labor, premature rupture of membranes, delivery date, and gestational age at delivery.


Eligibility criteria:
inclusion criteria: * pregnant, primigravid and multigravid women between the ages of 14 and 55, receiving prenatal care at usf health, stc, dept. of obstetrics. exclusion criteria: * presence of significant cardiac disease * renal disease * chronic hypertension * chromosomal abnormalities * cancer

Keywords: plac1 pregnant first prenatal visit pre-eclampsia
indicating direction and angle for cannulating of av-fistula in hemodialysis patients

Conditions: Chronic Kidney Disease; Kidney Failure

Summary: arteriovenous fistula is the preferred access for hemodialysis, and cannulation using a "button-hole" technique is increasingly recommended. by using the same two sites for cannulation there are reports of less risk of complications and less pain for the patient. however, button-hole cannulation can be difficult for the dialysis nurse, and failing cannulations can damage the av fistula and increase patient discomfort. the investigators therefore will test whether a simple marking on the skin of the direction and angle of cannulation used in each specific patient could improve the probability of a successful and painfree cannulation.


Eligibility criteria:
inclusion criteria: * chronic kidney disease * hemodialysis * arteriovenous fistula * established buttonhole technique * informed consent signed exclusion criteria: * child * minor * not speaking norwegian * not willing to sign informed consent

Keywords: hemodialysis cannulation av-fistula buttonhole technique
study of circadian clock properties in healthy subjects, obese and type 2 diabetic patients.

Conditions: Circadian Rhythm; Diabetes; Obesity

Summary: the investigators aimed to characterize human circadian clockwork in healthy individuals in comparison to obese and type 2 diabetic subjects, employing the noninvasive experimental approach allowing the study of circadian profile in human individuals.

the investigators specifically aim to obtain and analyze the circadian profile of skin fibroblasts from healthy, obese and t2d subjects. does circadian oscillator profile and its parameters (phase, period and amplitude) will differ between healthy individuals and obese/ t2d patients? skin biopsy will be performed in order to collect and culture skin fibroblast cells. in vivo bioluminescence recording will be performed in primary human skin fibroblast cells. the profiles obtained from 10 subjects in each group will be compared to their healthy counterparts. bmal1and per2 are clock genes. lentiviral transduction of bmal1-luciferase or per2-luciferase in fibroblasts allow observation of circadian oscillations using bioluminescence assay. phase, period length and amplitude are used to characterize the circadian rhythm.

Eligibility criteria:
inclusion criteria: * age 20-80 * consent obtained exclusion criteria: * neoplasia * inflammatory disease * allergy to lidocaine
mesenteric sparing surgery in laparoscopic colorectal resection for endometriosis

Conditions: Endometriosis; Bowel Endometriosis; Constipation

Summary: colorectal resection is a standard surgical treatment of bowel deep infiltrating endometriosis (die). nevertheless, concerns about different bowel functional outcomes related to radical surgery versus conservative surgery as shaving technique is a topic leading to much debate. different surgical approach are used to perform colorectal resection and there is not a standardized technique. for the same concerns, studies have addressed the mesenteric vascular and nerve preservation both in oncological and benign intestinal disease with improved functional outcome. therefore, the aim of this prospective study is to analyze feasibility and safety of mesenteric vascular and nerve sparing surgery in laparoscopic segmental colorectal resection for die with short and long term follow up. women with die ,that underwent laparoscopic segmental colorectal resection, will undergo resection performed with inferior mesenteric artery and branching arteries preservation by dissecting adherent to the intestinal wall with mesenteric vascularization and innervation entirely preserved. personal history, clinical data, surgical data, short and long term surgical complications and long term outcomes will be recorded. symptoms and bowel function will be evaluated before and after surgery.


Eligibility criteria:
inclusion criteria: * patients referred for bowel endometriosis requiring colorectal resection exclusion criteria: * none

Keywords: laparoscopy colorectal resection deep infiltrating endometriosis constipation
the effects of night shift work on health across the menstrual cycle

Conditions: Sleep Deprivation; Menstrual Cycle; Brain Health; Metabolism; Microbiota; Immune System

Summary: the study aims to investigate the effects of sleep deprivation on women's health across different phases of the menstrual cycle.

modern society demands around-the-clock services, with an estimated 20% of workers involved in night shifts. shift work disrupts the circadian rhythm and has been linked to increased risks of obesity, metabolic syndrome, glucose dysregulation, and immune system issues. sleep deprivation, especially during wakeful nights, is associated with elevated levels of central nervous system biomarkers like tau and amyloid-β proteins, which are implicated in brain disorders such as alzheimer's disease. however, the effects of sleep deprivation on women, particularly in relation to hormonal fluctuations during the menstrual cycle, remain largely unexplored. the menstrual cycle, which occurs in cis-women of childbearing age, involves significant fluctuations in estrogen, a hormone known for its neuroprotective properties. estrogen impacts memory, executive function, and may play a role in protecting against neurodegenerative conditions like alzheimer's disease. previous studies have largely focused on men or women using hormonal contraceptives, leaving a gap in understanding how natural hormonal cycles impact the response to sleep deprivation. this study addresses this gap by focusing on healthy young women with regular menstrual cycles who do not use hormonal contraceptives. participants will undergo an adaptation night followed by a sleep condition and a wake condition experiment. the goal is to better understand how hormonal changes throughout the menstrual cycle influence the body's response to sleep deprivation and stress, particularly in areas such as metabolism, brain function, and immune, system, and microbiota.

Eligibility criteria:
inclusion criteria: - healthy exclusion criteria: * use of hormonal contraceptives * chronic disease * regular use of nicotine * use of medication * consumes excessive amounts of alcohol or coffee

Keywords: estrogen
cerebral hemodynamics during sustained intra-operative hypotension

Conditions: Cerebral Autoregulation

Summary: objective: the objective of this study is to describe the physiology of the cerebral autoregulation over time during extreme low blood pressures (bp). study design: this is a retrospective data collection study. during the personalized external aortic root support (pears) procedure extreme low blood pressures \< 65 mmhg are medically induced. hemodynamic and neurophysiologic data is for clinic purposes stored. study population: all patients requiring a pears study at the amsterdam university medical centers, location amsterdam medical center (amc). investigation: cerebral parameters during sustained low blood pressures are monitored with the transcranial doppler (tcd) for cerebral blood flow velocity (cbfv), near infrared spectroscopy (nirs) for cerebral tissue oxygenation (rs02) and the electroencephalography (eeg) for the cerebral activity. blood pressure waveforms are retrieved from an invasive arterial catheter. besides, blood gasses during the low blood pressures and cardiac output, measured with a schwan ganz catheter are collected as well as electronic health records (ehr) (like age, gender and weight). all these devices are implemented as stated in the clinic protocol. main study parameters/endpoints: the investigators will describe the cerebral autoregulation (ca) in several ways to retrieve a cut-off or lower limit of the ca where the regulation is either intact or impaired. first the static ca will be created with the mean arterial pressure (map) and mean cerebral blood flow (cbfm), second, the ca will be described with the mean flow velocity index (mx, a method which calculates the correlation between the map and cbfm), cox (correlation between map and rs02) and with data of the eeg. after retrieval of the cut off or lower limit, the ca below this point will be described over time to check for differences.


Eligibility criteria:
inclusion criteria: * planned for a pears procedure * informed consent should be given exclusion criteria: * no informed consent

Keywords: cerebral autoregulation pears
implementation of home monitoring in patients with pulmonary fibrosis

Conditions: Pulmonary Fibrosis; Interstitial Lung Disease (ILD)

Summary: the objective of this study is to evaluate the impact of structurally replacing half of the outpatient clinic visits for patients with pulmonary fibrosis by home monitoring and video consultations on patient self-management and health(care) outcomes.

patients will be randomly assigned to receive either hospital-based care or a home monitoring program integrated into hospital-based care. hospital-based care involves outpatient clinic visits every three months including lung function testing. home monitoring involves weekly measurements of both physiological- and patient reported outcomes (pros) in a mobile health care application with half of the outpatient clinic visits alternately being replaced by remote video consultations. the home monitoring program includes home spirometry, pulse-oximetry, pros, video consultations, a medication coach, and an infotheque showing disease-specific information. questionnaires will be filled out by both study groups at set time points. the total study duration for individual patients will be 12 months.

Eligibility criteria:
inclusion criteria: * a multidisciplinary ild team diagnosis of pulmonary fibrosis according to ats/ers/jrs/alat guidelines; * adults (=/\>18 years). exclusion criteria: * patients who are not able to speak, read and/or write in dutch; * patients with no access to the internet; * patients with a life expectancy of less than 1 year as determined by the treating healthcare provider; * patients who are or have been using a home monitoring program for pf.

Keywords: ehealth hybrid care self-management